Cargando…

A unique peptide deformylase platform to rationally design and challenge novel active compounds

Peptide deformylase (PDF) is considered an excellent target to develop antibiotics. We have performed an extensive characterization of a new PDF from the pathogen Streptococcus agalactiae, showing properties similar to other known PDFs. S. agalactiae PDF could be used as PDF prototype as it allowed...

Descripción completa

Detalles Bibliográficos
Autores principales: Fieulaine, Sonia, Alves de Sousa, Rodolphe, Maigre, Laure, Hamiche, Karim, Alimi, Mickael, Bolla, Jean-Michel, Taleb, Abbass, Denis, Alexis, Pagès, Jean-Marie, Artaud, Isabelle, Meinnel, Thierry, Giglione, Carmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071857/
https://www.ncbi.nlm.nih.gov/pubmed/27762275
http://dx.doi.org/10.1038/srep35429
_version_ 1782461339017412608
author Fieulaine, Sonia
Alves de Sousa, Rodolphe
Maigre, Laure
Hamiche, Karim
Alimi, Mickael
Bolla, Jean-Michel
Taleb, Abbass
Denis, Alexis
Pagès, Jean-Marie
Artaud, Isabelle
Meinnel, Thierry
Giglione, Carmela
author_facet Fieulaine, Sonia
Alves de Sousa, Rodolphe
Maigre, Laure
Hamiche, Karim
Alimi, Mickael
Bolla, Jean-Michel
Taleb, Abbass
Denis, Alexis
Pagès, Jean-Marie
Artaud, Isabelle
Meinnel, Thierry
Giglione, Carmela
author_sort Fieulaine, Sonia
collection PubMed
description Peptide deformylase (PDF) is considered an excellent target to develop antibiotics. We have performed an extensive characterization of a new PDF from the pathogen Streptococcus agalactiae, showing properties similar to other known PDFs. S. agalactiae PDF could be used as PDF prototype as it allowed to get complete sets of 3-dimensional, biophysical and kinetic data with virtually any inhibitor compound. Structure-activity relationship analysis with this single reference system allowed us to reveal distinct binding modes for different PDF inhibitors and the key role of a hydrogen bond in potentiating the interaction between ligand and target. We propose this protein as an irreplaceable tool, allowing easy and relevant fine comparisons between series, to design, challenge and validate novel series of inhibitors. As proof-of-concept, we report here the design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug resistant clinical isolate.
format Online
Article
Text
id pubmed-5071857
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50718572016-10-26 A unique peptide deformylase platform to rationally design and challenge novel active compounds Fieulaine, Sonia Alves de Sousa, Rodolphe Maigre, Laure Hamiche, Karim Alimi, Mickael Bolla, Jean-Michel Taleb, Abbass Denis, Alexis Pagès, Jean-Marie Artaud, Isabelle Meinnel, Thierry Giglione, Carmela Sci Rep Article Peptide deformylase (PDF) is considered an excellent target to develop antibiotics. We have performed an extensive characterization of a new PDF from the pathogen Streptococcus agalactiae, showing properties similar to other known PDFs. S. agalactiae PDF could be used as PDF prototype as it allowed to get complete sets of 3-dimensional, biophysical and kinetic data with virtually any inhibitor compound. Structure-activity relationship analysis with this single reference system allowed us to reveal distinct binding modes for different PDF inhibitors and the key role of a hydrogen bond in potentiating the interaction between ligand and target. We propose this protein as an irreplaceable tool, allowing easy and relevant fine comparisons between series, to design, challenge and validate novel series of inhibitors. As proof-of-concept, we report here the design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug resistant clinical isolate. Nature Publishing Group 2016-10-20 /pmc/articles/PMC5071857/ /pubmed/27762275 http://dx.doi.org/10.1038/srep35429 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Fieulaine, Sonia
Alves de Sousa, Rodolphe
Maigre, Laure
Hamiche, Karim
Alimi, Mickael
Bolla, Jean-Michel
Taleb, Abbass
Denis, Alexis
Pagès, Jean-Marie
Artaud, Isabelle
Meinnel, Thierry
Giglione, Carmela
A unique peptide deformylase platform to rationally design and challenge novel active compounds
title A unique peptide deformylase platform to rationally design and challenge novel active compounds
title_full A unique peptide deformylase platform to rationally design and challenge novel active compounds
title_fullStr A unique peptide deformylase platform to rationally design and challenge novel active compounds
title_full_unstemmed A unique peptide deformylase platform to rationally design and challenge novel active compounds
title_short A unique peptide deformylase platform to rationally design and challenge novel active compounds
title_sort unique peptide deformylase platform to rationally design and challenge novel active compounds
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071857/
https://www.ncbi.nlm.nih.gov/pubmed/27762275
http://dx.doi.org/10.1038/srep35429
work_keys_str_mv AT fieulainesonia auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT alvesdesousarodolphe auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT maigrelaure auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT hamichekarim auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT alimimickael auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT bollajeanmichel auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT talebabbass auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT denisalexis auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT pagesjeanmarie auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT artaudisabelle auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT meinnelthierry auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT giglionecarmela auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT fieulainesonia uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT alvesdesousarodolphe uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT maigrelaure uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT hamichekarim uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT alimimickael uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT bollajeanmichel uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT talebabbass uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT denisalexis uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT pagesjeanmarie uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT artaudisabelle uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT meinnelthierry uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds
AT giglionecarmela uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds